Management of anticoagulants in the periprocedural period for patients with cancer

Anita Pudusseri, Alex C. Spyropoulos

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Patients with cancer undergo surgeries and procedures for various purposes, including prophylaxis, diagnosis, staging, cure, debulking, palliation, and reconstruction. The diagnosis of cancer itself, along with the well-established complication of venous thromboembolism (VTE), places these patients at risk for perioperative thromboembolism. It is also well-established that continuing patients on oral anticoagulation therapy during the periprocedural period is associated with an increased risk of bleeding. Rates of periprocedural VTE and major bleeding are significantly higher in patients with cancer, presenting a complex problem for clinicians in terms of periprocedural anticoagulation management. This article reviews the current recommendations regarding periprocedural anticoagulation management in patients with cancer.

Original languageEnglish
Pages (from-to)1713-1720
Number of pages8
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Issue number12
StatePublished - 1 Dec 2014
Externally publishedYes


Dive into the research topics of 'Management of anticoagulants in the periprocedural period for patients with cancer'. Together they form a unique fingerprint.

Cite this